167 related articles for article (PubMed ID: 4156624)
21. Penfluridol: an efficacious long-acting oral antipsychotic compound.
Gallant DM; Mielke DH; Spirtes MA; Swanson WC; Bost R
Am J Psychiatry; 1974 Jun; 131(6):699-702. PubMed ID: 4597305
[No Abstract] [Full Text] [Related]
22. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
Quraishi S; David A
Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of pipotiazine palmitate (19.552 R.P.) used on patients in an acute reception ward.
Elley JH; Petersen JH
Acta Psychiatr Scand Suppl; 1973; 241():75-82. PubMed ID: 4147514
[No Abstract] [Full Text] [Related]
24. Controlled clinical evaluation of depot neuroleptics. A double-blind trial with pipotiazine undecylenate and fluphenazine enanthate.
Ahlfors UG
Acta Psychiatr Scand Suppl; 1973; 241():95-9. PubMed ID: 4147516
[No Abstract] [Full Text] [Related]
25. A long-term pilot study of pipothiazine palmitate in chronic schizophrenia.
Villeneuve A; Pires A; Jus A; Lachance R; Drolet A
Curr Ther Res Clin Exp; 1972 Nov; 14(11):696-706. PubMed ID: 4404626
[No Abstract] [Full Text] [Related]
26. Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia.
Gerlach J; Kramp P; Kristjansen P; Lauritsen B; Lühdorf K; Munkvad I
Acta Psychiatr Scand; 1975 Aug; 52(2):132-44. PubMed ID: 1096541
[TBL] [Abstract][Full Text] [Related]
27. [Aspects of neuroleptic depot therapy with special consideration of clinical experiences with the preoral depot preparation Penfluridol (R 16 341-Jannsen)].
Bruck J; Guss H
Int Pharmacopsychiatry; 1974; 9(3):152-65. PubMed ID: 4154320
[No Abstract] [Full Text] [Related]
28. Clinical evaluation of a new depot neuroleptic. A pilot study with pipotiazine undecylenate (19.551 R.P.).
Ahlfors UG; Katila O
Acta Psychiatr Scand Suppl; 1973; 241():43-9. PubMed ID: 4147510
[No Abstract] [Full Text] [Related]
29. [Experiences with depot-neuroleptics in an after-care unit. Organization of the therapy exemplified with pipotiazine palmitate].
Salvesen C; Vaksdal K
Tidsskr Nor Laegeforen; 1973 Aug; 93(24):1699-703. PubMed ID: 4149082
[No Abstract] [Full Text] [Related]
30. Fluspirilene and pipothiazine undecylenate, two long-acting injectable neuroleptics. A double-blind controlled trial in residual schizophrenia.
Vereecken JL; Tanghe A
Psychiatr Neurol Neurochir; 1972; 75(2):117-27. PubMed ID: 5030483
[No Abstract] [Full Text] [Related]
31. Dexetimide: an effective drug for the control of extrapyramidal symptoms induced by pipothiazine palmitate.
Dom R; Van Lommel R; Baro F
Acta Psychiatr Scand; 1973; 49(5):563-9. PubMed ID: 4148581
[No Abstract] [Full Text] [Related]
32. Evaluation of piperacetazine (Quide) injection in acute schizophrenics.
Kiev A; Güclü B; Kulkarni AS
Curr Ther Res Clin Exp; 1972 Jul; 14(7):376-80. PubMed ID: 4625517
[No Abstract] [Full Text] [Related]
33. Depot fluphenazine and flupenthixol in the treatment of stabilized schizophrenics. A double-blind comparative trial.
Chowdhury ME; Chacon C
Compr Psychiatry; 1980; 21(2):135-9. PubMed ID: 6991205
[No Abstract] [Full Text] [Related]
34. Monthly intermittent chemotherapy of chronic schizophrenic outpatients with pipothiazine palmitate.
Laurent JS; Carle R; Dumais B; Domingue D
Can Psychiatr Assoc J; 1974 Dec; 19(6):583-91. PubMed ID: 4155349
[No Abstract] [Full Text] [Related]
35. Pipotiazine palmitate: an evaluation of a new long acting intramuscular antipsychotic agent in severely ill schizophrenic patients.
Gallant DM; Mielke D; Bishop G; Oelsner T; Guerrero-Figueroa R
Dis Nerv Syst; 1975 Apr; 36(4):193-6. PubMed ID: 1090427
[TBL] [Abstract][Full Text] [Related]
36. A 5-year follow-up study of chronic schizophrenics treated with clopenthixol decanoate.
Carney MW
Pharmatherapeutica; 1984; 4(1):57-63. PubMed ID: 6150493
[TBL] [Abstract][Full Text] [Related]
37. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry.
Martyns-Yellowe IS
West Afr J Med; 1993; 12(2):110-3. PubMed ID: 8104468
[TBL] [Abstract][Full Text] [Related]
38. Rational use of psychotropic drugs. III. Major tranquilizers.
Greenblatt DJ; Shader RI
Am J Hosp Pharm; 1974 Dec; 31(12):1226-31. PubMed ID: 4156455
[No Abstract] [Full Text] [Related]
39. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology.
Wistedt B; Ranta J
Acta Psychiatr Scand; 1983 Jun; 67(6):378-88. PubMed ID: 6349256
[TBL] [Abstract][Full Text] [Related]
40. Differential study of 2 long-acting neuroleptics, fluphenazine enanthate and pipothiazine undecylenate.
Gayral LF; Escande MM; Fournie HC; Huron RJ
Therapie; 1973; 28(3):611-25. PubMed ID: 4771904
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
